Исследования и практика в медицине №04 2021

Список исп. литературыСкрыть список

1. Камалов А.А, Самоходская Л.М., Карпов В.К, Охоботов Д.А., Мамедов В.Н. Маркеры рака предстательной железы и потенциал
использования АПФ, вырабатываемого простотой, в диагностике рака предстательной железы и доброкачественной
гиперплазии предстательной железы. Урология. 2019;(2):73–81. https://doi.org/10.18565/urology.2019.2.73-81
2. Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med. 2020 Feb 25;58(3):326–339.
https://doi.org/10.1515/cclm-2019-0693
3. American Cancer Society. Cancer Facts & Figures, 2017. Доступно по: https://www.cancer.org/content/dam/cancer-org/research/
cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf, Дата обращения: 19.05.2021.
4. Тороповский А.Н, Никитин А.Г, Павлова О.Н, Викторов Д.А. Перспективы совершенствования диагностики рака предстатель-
ной железы на основе анализа экспрессии гена PCA3. Урология. 2019;(2):82–86. https://doi.org/10.18565/urology.2019.2.82-86
5. Postma R, Schröder FH. Screening for prostate cancer. Eur J Cancer. 2005 Apr;41(6):825–833. https://doi.org/10.1016/j.ejca.2004.12.029
6. Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and
the prostate health index for detecting prostate cancer. Clin Chem. 2013 Jan;59(1):306–314. https://doi.org/10.1373/clinchem.2012.195784
7. Ружанская А. В, Евгина С. А., Скибо И. И. Практическое использование маркера -2проПСА и индекса здоровья простаты PHI
в диагностике рака предстательной железы. Клиническая лабораторная диагностика. 2014;59(1):4–8.
8. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2]pro-prostate specific antigen combined
with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate
specific antigen range. J Urol. 2011 May;185(5):1650–1655. https://doi.org/10.1016/j.juro.2010.12.032
9. De la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive
Prostate Cancer in Biopsy Naïve Men. J Urol. 2015 Jul;194(1):65–72. https://doi.org/10.1016/j.juro.2015.01.091
10. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, et al. The prostate health index selectively identifies clinically significant
prostate cancer. J Urol. 2015 Apr;193(4):1163–1169. https://doi.org/10.1016/j.juro.2014.10.121
11. White J, Shenoy BV, Tutrone RF, Karsh LI, Saltzstein DR, Harmon WJ, et al. Clinical utility of the Prostate Health Index (phi) for biopsy
decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis. 2018 Apr;21(1):78–84.
https://doi.org/10.1038/s41391-017-0008-712. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. Reducing unnecessary biopsy during prostate cancer
screening using a four-kallikrein panel: an independent replication. J Clin Oncol. 2010 May 20;28(15):2493–2498.
https://doi.org/10.1200/JCO.2009.24.1968
13. Zappala SM, Dong Y, Linder V, Reeve M, Sjoberg DD, Mathur V, et al. The 4Kscore blood test accurately identifies men with aggressive
prostate cancer prior to prostate biopsy with or without DRE information. Int J Clin Pract. 2017 Jun;71(6):e12943.
https://doi.org/10.1111/ijcp.12943
14. McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, Belzer S, et al. A Novel Urine Exosome Gene Expression Assay to Predict
High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016 Jul 1;2(7):882–889. https://doi.org/10.1001/jamaoncol.2016.0097
15. Mottet N N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer.
Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618–629.
https://doi.org/10.1016/j.eururo.2016.08.003
16. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, et al. NCCN Guidelines Insights: Prostate Cancer Early Detection,
Version 2.2016. J Natl Compr Canc Netw. 2016 May;14(5):509–519. https://doi.org/10.6004/jnccn.2016.0060
17. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene
mutation in prostate cancer. Carcinogenesis. 2011 May;32(5):772–778. https://doi.org/10.1093/carcin/bgr036
18. Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Lett. 2017 Oct
28;407:9–20. https://doi.org/10.1016/j.canlet.2017.08.011
19. Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 2019
Feb;21(2):126–144. https://doi.org/10.1007/s12094-018-1910-8
20. Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, et al. Preoperative Prostate-specific Antigen Isoform p2PSA and
Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for
Prostate Cancer: Results from a Multicentric European Prospective Study. Eur Urol. 2015 Jul;68(1):132–138.
https://doi.org/10.1016/j.eururo.2014.07.034
21. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate
cancer. Urology. 2004 Aug;64(2):311–315. https://doi.org/10.1016/j.urology.2004.03.052
22. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with
serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2013 Jul;31(5):566–571. https://doi.org/10.1016/j.urolonc.2011.04.001
23. Wang T, Qu X, Jiang J, Gao P, Zhao D, Lian X, et al. Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer.
Oncotarget. 2017 Aug 29;8(35):58577–58586. https://doi.org/10.18632/oncotarget.17272
24. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, et al. Initial prostate biopsy: development and internal
validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2013 Feb;63(2):201–209.
https://doi.org/10.1016/j.eururo.2012.07.030
25. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, et al. PCA3 molecular urine test as a predictor of repeat
prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013 Jul;190(1):64–
69. https://doi.org/10.1016/j.juro.2013.02.018
26. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative effectiveness review: prostate cancer antigen 3 testing
for the diagnosis and management of prostate cancer. J Urol. 2013 Aug;190(2):389–398. https://doi.org/10.1016/j.juro.2013.02.005
27. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, et al. Can urinary PCA3 supplement PSA in the early detection of prostate
cancer? J Clin Oncol. 2014 Dec 20;32(36):4066–4062. https://doi.org/10.1200/JCO.2013.52.8505
28. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular
extension and tumor volume. J Urol. 2008 Nov;180(5):1975–1978. https://doi.org/10.1016/j.juro.2008.07.060
29. Turner AR, Feng J, Liu W. Prostate Cancer. Genomic and Personalized Medicine. 2nd Edn. Ch. 63. London: Academic Press. 2012,
733–741 p.
30. Li LC, Hsieh AC, Ruggero D. et al. Molecular basis of prostate cancer. Ch. 38. In: Mendelsohn J, Howley PM, Israel MA, et al. The
molecular basis of cancer. 4th Edn. Philadelphia: Elsevier. 2015, 888 p.
31. Lamy P-J, Allory Y, Gauchez A-S, Asselain B, Beuzeboc P, de Cremoux P, et al. Prognostic Biomarkers Used for Localised Prostate
Cancer Management: A Systematic Review. Eur Urol Focus. 2018 Dec;4(6):790–803. https://doi.org/10.1016/j.euf.2017.02.017
32. Tomlins SA, Aubin SMJ, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate
cancer risk in men with elevated serum PSA. Sci Transl Med. 2011 Aug 3;3(94):94ra72. https://doi.org/10.1126/scitranslmed.3001970
33. Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, et al. Association Between Combined TMPRSS2:ERG and PCA3
RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol. 2017 Aug 1;3(8):1085–1093.
https://doi.org/10.1001/jamaoncol.2017.0177
34. Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate
Cancer Risk Assessment. Eur Urol. 2016 Jul;70(1):45–53. https://doi.org/10.1016/j.eururo.2015.04.039
35. McLeod DG, Petrovics G. Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive
Prostate Cancer. Eur Urol. 2018 Feb;73(2):301–302. https://doi.org/10.1016/j.eururo.2017.09.03536. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, et al. Evaluation of the ETS-related gene mRNA in urine for the detection
of prostate cancer. Clin Cancer Res. 2010 Mar 1;16(5):1572–1576. https://doi.org/10.1158/1078-0432.CCR-09-2191
37. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, et al. Detection of High-grade Prostate Cancer Using
a Urinary Molecular Biomarker-Based Risk Score. Eur Urol. 2016 Nov;70(5):740–748. https://doi.org/10.1016/j.eururo.2016.04.012
38. Филатов М.В., Ланда С.Б., Пантина Р.А., Гармай Ю.П. Исследование экзосом, секретируемых различными нормальными и
злокачественно трансформированными клетками in vitro и in vivo. Клиническая лабораторная диагностика. 2010;(12):35–43.
39. Nazimek K, Bryniarski K, Santocki M, Ptak W. Exosomes as mediators of intercellular communication: clinical implications. Pol Arch
Med Wewn. 2015;125(5):370–380. https://doi.org/10.20452/pamw.2840
40. Малек А. В., Берштейн Л. М., Филатов М. В, Беляев А. М. Система экзосомальных межклеточных коммуникаций и ее роль
в процессе метастатической диссеминации. Вопросы онкологии. 2014;60(4):429–437.
41. Drake RR, Kislinger T. The proteomics of prostate cancer exosomes. Expert Rev Proteomics. 2014 Apr;11(2):167–177.
https://doi.org/10.1586/14789450.2014.890894
42. Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic
and therapeutic implications (Review). Int J Oncol. 2015 Jan;46(1):17–27. https://doi.org/10.3892/ijo.2014.2712
43. Van Neste L, Partin AW, Stewart GD, Epstein JI, Harrison DJ, Van Criekinge W. Risk score predicts high-grade prostate cancer in DNA-methylation
positive, histopathologically negative biopsies. Prostate. 2016 Sep;76(12):1078–1087. https://doi.org/10.1002/pros.23191
44. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, et al. Convergence of mutation and epigenetic alterations identifies common
genes in cancer that predict for poor prognosis. PLoS Med. 2008 May 27;5(5):e114. https://doi.org/10.1371/journal.pmed.0050114
45. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, et al. Clinical validation of an epigenetic assay to predict negative
histopathological results in repeat prostate biopsies. J Urol. 2014 Oct;192(4):1081–1087. https://doi.org/10.1016/j.juro.2014.04.013
46. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis.
Prostate. 2012 Aug 1;72(11):1248–1261. https://doi.org/10.1002/pros.22459
47. Wang W, Wang M, Wang L, Adams TS, Tian Y, Xu J. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate
cancer: a meta-analysis. Sci Rep. 2014 May 23;4:5012. https://doi.org/10.1038/srep05012
48. Stewart GD, Van Neste L, Delvenne P, Delrée P, Delga A, McNeill SA, et al. Clinical utility of an epigenetic assay to detect occult
prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013 Mar;189(3):1110–1116.
https://doi.org/10.1016/j.juro.2012.08.219
49. Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP, Shan J, Han JS, et al. A Biopsy-based 17-gene Genomic Prostate Score as
a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. Eur Urol. 2018
Jan;73(1):129–138. https://doi.org/10.1016/j.eururo.2017.09.013
50. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence
After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and
Intermediate-risk Prostate Cancer. Eur Urol. 2015 Jul;68(1):123–131. https://doi.org/10.1016/j.eururo.2014.11.030
51. Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc
Netw. 2016 Jan;14(1):19–30. https://doi.org/10.6004/jnccn.2016.0004
52. Klein EA, Haddad Z, Yousefi K, Lam LLC, Wang Q, Choeurng V, et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts
Metastasis Risk. Urology. 2016 Apr;90:148–152. https://doi.org/10.1016/j.urology.2016.01.012
53. Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, et al. Ability of a Genomic Classifier to Predict Metastasis and
Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017 Nov;72(5):845–852.
https://doi.org/10.1016/j.eururo.2017.05.009